Drug Trial Radar · NCT07749911
Assessing Vaccine Effectiveness of R21/Matrix-M Across Malaria Transmission Settings (AVERT)
Last checked: Nov 20, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20,000
Planned (sponsor's estimate)
Start
Jul 14, 2026
Primary completion
Jun 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- Clinton Health Access Initiative Inc.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of California, San Francisco; Infectious Diseases Research Collaboration, Uganda; Institut de Recherche en Sciences de la Sante, Burkina Faso; Ministry of Health, Burkina Faso; Ministry of Health, Uganda
- First posted
- Aug 6, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 5 months, up to 5 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The AVERT study is a prospective observational test-negative case control study evaluating the real-world effectiveness of the R21/Matrix-M malaria vaccine among children younger than 5 years in Burkina Faso and Uganda. Children who seek outpatient care with suspected malaria and are eligible for the national R21/Matrix-M vaccination program will be enrolled. Malaria infection will be determined by blood smear microscopy. Children with a positive microscopy result will be classified as cases and children with a negative result as controls. Vaccination history, including the number and timing of doses, will be obtained primarily from vaccination cards or other written records. Vaccine effectiveness will be estimated by comparing the odds of vaccination among cases and controls.
Conditions
- Malaria
- PLASMODIUM FALCIPARUM MALARIA
Interventions
R21/Matris-M Malaria vaccineBiological
R21/Matrix-M vaccination received through routine national immunization programs. The study will record the number and dates of doses received. Children will be classified as having received 0, 1, 2, 3, or 4 eligible doses, with prespecified grouped classifications used if individual dose categories are underpowered. Doses given fewer than 14 days before malaria testing will not count toward the primary exposure classification.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-specific effectiveness of R21/Matrix-M against microscopy-confirmed clinical malariaTime frame: At the enrollment illness episode, during the approximately 7- to 8-month study recruitment period
Locations
21 sites in 2 countries. Site status is shown where the registry gives one.
Boromo urbain 1
Boromo, Boucle Mouhoun, Burkina Faso · Recruiting
Ouahabou
Boromo, Boucle Mouhoun, Burkina Faso · Recruiting
Béréba
Houndé, Hauts-Bassins Region, Burkina Faso · Recruiting
Dohoun
Houndé, Hauts-Bassins Region, Burkina Faso · Recruiting
Kari
Houndé, Hauts-Bassins Region, Burkina Faso · Recruiting
Déguélin
Karangasso-Vigué, Hauts-Bassins Region, Burkina Faso · Recruiting
Karangasso-Vigué
Karangasso-Vigué, Hauts-Bassins Region, Burkina Faso · Recruiting
Sourmousso
Karangasso-Vigué, Hauts-Bassins Region, Burkina Faso · Recruiting
Wara
Karangasso-Vigué, Hauts-Bassins Region, Burkina Faso · Recruiting
Mankarga T
Zorgo, Oubri, Burkina Faso · Recruiting
Mankarga V3
Zorgo, Oubri, Burkina Faso · Recruiting
Mankarga V6
Zorgo, Oubri, Burkina Faso · Recruiting
Kitgum-Matidi HCIII
Kitgum, Acholi, Uganda · Not yet recruiting
Namokora HCIV
Kitgum, Acholi, Uganda · Not yet recruiting
Lalogi HCIV
Omoro, Acholi, Uganda · Not yet recruiting
Rwenyawawa HCIII
Kikube, Bunyoro, Uganda · Not yet recruiting
Nawaikoke HCIII
Kaliro, Busoga, Uganda · Not yet recruiting
Kigandalo HCIV
Mayuge, Busoga, Uganda · Not yet recruiting
Nadunget HCIII
Moroto, Karamoja, Uganda · Not yet recruiting
Orum HCIV
Otuke, Lango, Uganda · Not yet recruiting
Otwal HCIII
Oyam, Lango, Uganda · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.